Perrigo Company plc
) and partner Catalent Pharma Solutions have settled their patent
related dispute with
Teva Pharmaceutical Industries Limited
) pertaining to Teva's respiratory drug ProAir HFA. Following the
settlement, Perrigo and Catalent can sell limited units of
Perrigo's generic version of the inhaler from Dec 19, 2016 through
Jun 30, 2018, The limits will no longer be applicable after Jun 30,
We note that ProAir is marketed for the treatment or prevention of
bronchospasm with reversible obstructive airway disease as well as
the prevention of exercise-induced bronchospasm in patients aged
fours years and above. The branded version of the drug recorded
sales of approximately $1.4 billion over the past 52 weeks
according to the data released by Symphony Health Solutions.
We remind investors that Perrigo had filed an abbreviated new drug
application with the FDA, seeking to market its generic version of
ProAir HFA in 2012. Teva had challenged the application. However,
the litigation has been dismissed following the settlement.
The generic segment at Perrigo (Rx Pharmaceuticals) has been
performing encouragingly buoyed by quite a few approvals over the
past few months. Segmental sales climbed 18% year over year to
$223.4 million in the third quarter of fiscal 2014 (ended Mar 29,
2014). The performance of the segment was a bright spot in what was
a disappointing quarter for Perrigo otherwise. Perrigo expects
fiscal 2014 revenues from the segment to grow in the range of 26%
to 30% on a year-over-year basis.
Perrigo carries a Zacks Rank #3 (Hold). Some better-ranked stocks
in the healthcare sector include
). Both the stocks carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
REGENERON PHARM (REGN): Free Stock Analysis
TEVA PHARM ADR (TEVA): Free Stock Analysis
PERRIGO CO PLC (PRGO): Free Stock Analysis
MALLINCKRODT PL (MNK): Free Stock Analysis
To read this article on Zacks.com click here.